Company Filing History:
8 out of 130 
1 out of 16 Years Active: 2011-2020
Title: Sharon Rae Engel: Advancing CNS Disorder Treatment with Innovative Patents
Introduction:
In the field of pharmaceuticals and the treatment of central nervous system (CNS) disorders, inventors like Sharon Rae Engel play a crucial role. With a strong background in the development of novel compounds and extensive experience in the industry, Sharon Rae Engel has made significant contributions to the medical field, particularly in the area of monoamine reuptake inhibitors. In this article, we will explore some of Engel's latest patents, career highlights, and notable collaborations.
Latest Patents:
Sharon Rae Engel has a commendable track record, with eight patents to their name. One of their most recent patented inventions involves the use of cyclohexylamine derivatives as monoamine reuptake inhibitors. These compounds have demonstrated potential for the treatment and prevention of various CNS disorders, ranging from depression and anxiety to schizophrenia and sleep disorders. Engel's innovative patents not only showcase their expertise but also highlight their dedication to improving patient outcomes and addressing unmet medical needs.
Career Highlights:
Engel's career spans multiple prestigious companies in the pharmaceutical industry. They have contributed significantly to the success and advancement of companies such as Sunovion Pharmaceuticals Inc., a global leader in psychiatric and neurological medications. Sunovion Pharmaceuticals Inc. has benefited from Engel's expertise in developing therapeutic compounds and enhancing treatment options for patients with CNS disorders.
Another noteworthy company Engel has collaborated with is PGI Drug Discovery LLC. PGI Drug Discovery LLC is an esteemed pharmaceutical research and development organization focused on innovative drug discovery. Engel's contributions to this company have likely propelled research efforts in identifying promising compounds to address CNS disorders.
Collaborations:
In the pursuit of groundbreaking innovations, Sharon Rae Engel has collaborated with accomplished professionals in the industry. Notably, Engel has worked alongside respected colleagues like Liming Shao and Fengjiang Wang. These partnerships have undoubtedly fostered a collaborative environment, allowing for the exchange of ideas and expertise to drive progress within the field of CNS disorder treatment.
Conclusion:
Sharon Rae Engel's patents and contributions to the pharmaceutical industry, particularly in the development of monoamine reuptake inhibitors, highlight their dedication to advancing treatment options for individuals with CNS disorders. Engel's work at notable companies like Sunovion Pharmaceuticals Inc. and collaborations with esteemed professionals demonstrate their commitment to innovation and improving patient outcomes. As the field of CNS disorder treatment continues to evolve, Sharon Rae Engel's contributions will undoubtedly play a vital role in shaping the future of therapeutic interventions.